Premium
Chlorpromazine‐induced vanishing bile duct syndrome leading to biliary cirrhosis
Author(s) -
Moradpour Darius,
Altorfer Josef,
Flury Renata,
Greminger Peter,
Meyenberger Christa,
Jost Res,
Schmid Martin
Publication year - 1994
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840200610
Subject(s) - jaundice , cholestasis , medicine , gastroenterology , ursodeoxycholic acid , biliary cirrhosis , primary biliary cirrhosis , bile duct , steatorrhea , alkaline phosphatase , cirrhosis , elevated alkaline phosphatase , disease , chemistry , biochemistry , autoimmune disease , enzyme
We describe a 33‐yr‐old pregnant woman in whom a primary biliary cirrhosis—like syndrome developed after 2 wk of chlorpromazine therapy. The clinical course was characterized by severe jaundice lasting 22 mo, intense pruritus, fever, steatorrhea, high alkaline phosphatase levels and hypercholesterolemia. Jaundice resolved with initiation of ursodeoxycholic acid therapy, but subclinical cholestasis and low‐level inflammatory activity persisted and ultimately evolved into biliary cirrhosis. The pathological substrate of this severe and prolonged cholestatic reaction was found to be the vanishing bile duct syndrome with a marked transient pseudoxanthomatosis. (Hepatology 1994;20:1437–1441).